{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:13:13Z","timestamp":1790917993970,"version":"4.1.0"},"reference-count":31,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,7,1]]},"abstract":"<jats:p>Objective. Although universal immunization against Bordetella pertussis (whooping cough) infection has resulted in dramatic reductions in the incidence of pertussis, outbreaks continue to occur in countries with excellent vaccine coverage. Treatment of infection may ameliorate symptom severity during the catarrhal phase of pertussis but has no effect on established paroxysms, emesis, or apnea if given during the paroxysmal or convalescent phases. Erythromycin, recommended for treatment of pertussis to prevent transmission of infection, is poorly tolerated because of gastrointestinal side effects. We compared the safety and efficacy of erythromycin with azithromycin for treatment of pertussis in a large, randomized, controlled trial that enrolled children from primary care practices in 1 American and 11 Canadian urban centers.<\/jats:p>\n               <jats:p>Methods. Children who were 6 months to 16 years of age and had cough illness that was suspected to be or was culture confirmed as pertussis were randomized to azithromycin (10 mg\/kg on day 1 and 5 mg\/kg on days 2\u20135 as a single dose) or erythromycin estolate (40 mg\/kg\/day in 3 divided doses for 10 days) with stratification by center. The primary outcome measure was bacteriologic cure of infection as determined by cultures of nasopharyngeal aspirates. Culture-positive participants had a second aspirate collected at the end of therapy (days 5\u20137 for azithromycin, days 10\u201312 for erythromycin) and 1 week after therapy. Bacteriologic cure was defined as negative cultures at the end of therapy. Bacteriologic relapse was defined as a positive culture 1 week after completion of therapy and after a negative end-of-therapy culture. Secondary outcomes were pertussis diagnosed by serology and polymerase chain reaction (PCR), treatment-associated adverse events, compliance, and presence of clinical symptoms at the end of the treatment course. Serology was performed using standard enzyme-linked immunosorbent assay methods. A participant was considered to have pertussis when the PCR was positive or a 4-fold increase in pertussis toxin antibody between baseline and follow-up visits was observed. PCR was performed using a 1046-bp ClaI DNA fragment from B pertussis. Adverse events (nausea, vomiting, diarrhea, any gastrointestinal complaint, or other) were determined by a parent-completed diary that was reviewed with study personnel during study visits. Compliance was measured by review of the parent medication diary during study visits and observation of medication containers by the pharmacist at study completion. Symptoms were determined by history collected by study personnel at enrollment and subsequently from the diary. The design of the study was an equivalence trial, aimed at demonstrating that the bacteriologic failure rates with the 2 therapies did not differ by &amp;gt;8%. For the safety analysis, all participants who received at least 1 dose of study drug were included. In the per-protocol efficacy analysis, all culture-positive participants with end-of-treatment cultures were considered.<\/jats:p>\n               <jats:p>Results. A total of 477 children were enrolled and randomly assigned to either azithromycin (n = 239) or erythromycin (n = 238). Of these children, 114 (24%) grew B pertussis from nasopharyngeal specimens (azithromycin group: 58 of 239 [24%]; erythromycin group: 56 of 238 [23%]); these children composed the efficacy cohort for the per-protocol and intention-to-treat analyses. Serology and PCR added 52 children to the number considered to have pertussis for a total of 35% (166 of 477) of all children who presented with cough illness. In the safety analysis (antibiotic side effects, compliance) and comparison of cough symptoms after treatment, all randomized children are reported in their assigned treatment group. At end of therapy, bacterial eradication was demonstrated in all 53 patients in the azithromycin group and all 53 patients in the erythromycin group with follow-up cultures available (eradication 100%; 95% confidence interval [CI]: 93.3\u2013100). No bacterial recurrence was demonstrated in children with 1 week posttreatment nasopharyngeal cultures available (51 and 53 participants in the azithromycin and erythromycin arms, respectively [0%, 95% CI: 0\u20137.0; and 0%, 95% CI: 0\u20136.7]). No serious adverse events attributable to study drug were observed. Gastrointestinal adverse events were reported less frequently in azithromycin (18.8%; 45 of 239) than in erythromycin estolate (41.2%; 98 of 238) recipients (90% CI on difference: \u221229.0% to \u221215.7%) as a result of less nausea (2.9% vs 8.4%; 95% CI: \u22128.9% to \u22122.0%), less vomiting (5.0% vs 13.0%; 95% CI: \u22124.9% to \u22121.4%), and less diarrhea (7.1% vs 11.8%; 95% CI: \u22129.0% to \u22120.3%). Children who were randomized to azithromycin were much more likely to have complied with antimicrobial therapy over the treatment period. In the azithromycin group, 90% of children took 100% of prescribed doses, whereas only 55% of children in the erythromycin group took 100% of prescribed doses.<\/jats:p>\n               <jats:p>Conclusions. In this large, multicenter, randomized trial, we found that azithromycin is as effective as erythromycin estolate for the treatment of pertussis in children. Gastrointestinal adverse events were much more common with erythromycin treatment than azithromycin. Compliance with therapy was markedly better with azithromycin than with erythromycin in this study.<\/jats:p>","DOI":"10.1542\/peds.114.1.e96","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"e96-e101","source":"Crossref","is-referenced-by-count":96,"title":["Azithromycin Is as Effective as and Better Tolerated Than Erythromycin Estolate for the Treatment of Pertussis"],"prefix":"10.1542","volume":"114","author":[{"given":"Joanne M.","family":"Langley","sequence":"first","affiliation":[{"name":"Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Canada"},{"name":"Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Halperin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada"},{"name":"Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc\u0327ois D.","family":"Boucher","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de l\u2019Universite\u0301 Laval, Laval, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Smith","sequence":"additional","affiliation":[{"name":"Clinical Trials Research Center, IWK Health Centre, Dalhousie University, Halifax, Canada"},{"name":"Department of Mathematics and Statistics, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,7,1]]},"reference":[{"key":"2021121006501233500_R1","unstructured":"Pertussis\u2014United States, 1997\u20132000. MMWR Morb Mortal Wkly Rep.\u20082002;51:73\u201376"},{"key":"2021121006501233500_R2","doi-asserted-by":"crossref","unstructured":"Skowronski DM, De Serres G, MacDonald D, et al. The changing age and seasonal profile of pertussis in Canada. J Infect Dis.\u20082002;185:1448\u20131453","DOI":"10.1086\/340280"},{"key":"2021121006501233500_R3","doi-asserted-by":"crossref","unstructured":"Khetsuriani N, Bisgard K, Prevots DR, et al. Pertussis outbreak in an elementary school with high vaccination coverage. Pediatr Infect Dis J.\u20082001;20:1108\u20131112","DOI":"10.1097\/00006454-200112000-00003"},{"key":"2021121006501233500_R4","unstructured":"Cordova SP, Gilles MT, Beers MY. The outbreak that had to happen: Bordetella pertussis in north-west Western Australia in 1999. Commun Dis Intell.\u20082000;24:375\u2013379"},{"key":"2021121006501233500_R5","doi-asserted-by":"crossref","unstructured":"de Melker HE, Schellekens JF, Neppelenbroek SE, et al. Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis.\u20082000;6:348\u2013357","DOI":"10.3201\/eid0604.000404"},{"key":"2021121006501233500_R6","doi-asserted-by":"crossref","unstructured":"Crowcroft NS, Andrews N, Rooney C, et al. Deaths from pertussis are underestimated in England. Arch Dis Child.\u20082002;86:336\u2013338","DOI":"10.1136\/adc.86.5.336"},{"key":"2021121006501233500_R7","doi-asserted-by":"crossref","unstructured":"von Ko\u0308nig CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis.\u20082002;2:744\u2013750","DOI":"10.1016\/S1473-3099(02)00452-8"},{"key":"2021121006501233500_R8","doi-asserted-by":"crossref","unstructured":"Halperin SA, Wang EEL, Law B, et al. Epidemiological features of pertussis in hospitalized patients in Canada, 1991\u20131997: report of the Immunization Monitoring Program\u2013Active (IMPACT). Clin Infect Dis.\u20081999;28:1238\u20131243","DOI":"10.1086\/514792"},{"key":"2021121006501233500_R9","doi-asserted-by":"crossref","unstructured":"Bergquist SO, Bernander S, Dahnsjo H, Sundelof B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J.\u20081987;6:458\u2013461","DOI":"10.1097\/00006454-198705000-00009"},{"key":"2021121006501233500_R10","unstructured":"American Academy of Pediatrics. Pertussis. In: Pickering LK, ed. Red Book: 2003 Report of the Committee of Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2003:474"},{"key":"2021121006501233500_R11","doi-asserted-by":"crossref","unstructured":"Halperin SA, Bortolussi R, Langley JM, et al. Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics.\u20081997;100:65\u201371","DOI":"10.1542\/peds.100.1.65"},{"key":"2021121006501233500_R12","doi-asserted-by":"crossref","unstructured":"Halperin SA, Bortolussi R, Langley JM, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics.\u20081999;104(4). Available at: www.pediatrics.org\/cgi\/content\/full\/104\/4\/e42","DOI":"10.1542\/peds.104.4.e42"},{"key":"2021121006501233500_R13","doi-asserted-by":"crossref","unstructured":"Dodhia H, Miller E. Review of the evidence for the use of erythromycin in the management of persons exposed to pertussis. Epidemiol Infect.\u20081998;120:143\u2013149","DOI":"10.1017\/S0950268897008571"},{"key":"2021121006501233500_R14","doi-asserted-by":"crossref","unstructured":"Ramgoolam A, Steele R. Formulations of antibiotics for children in primary care: effects on compliance and efficacy. Paediatr Drugs.\u20082002;4:323\u2013333","DOI":"10.2165\/00128072-200204050-00005"},{"key":"2021121006501233500_R15","unstructured":"National Advisory Committee on Immunization (NACI), Advisory Committee on Epidemiology, Canadian Paediatric Society. Statement on management of persons exposed to pertussis and pertussis outbreak control. Can Commun Dis Rep.\u20081994;20:193\u2013199"},{"key":"2021121006501233500_R16","doi-asserted-by":"crossref","unstructured":"Halperin SA, Bortolussi R, Wort AJ. Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. J Clin Microbiol.\u20081989;27:752\u2013757","DOI":"10.1128\/jcm.27.4.752-757.1989"},{"key":"2021121006501233500_R17","doi-asserted-by":"crossref","unstructured":"Halperin SA, Kasina A, Swift M. Prolonged survival of Bordetella pertussis in a simple buffer after nasopharyngeal secretion aspiration. Can J Microbiol.\u20081992;38:1210\u20131213","DOI":"10.1139\/m92-200"},{"key":"2021121006501233500_R18","doi-asserted-by":"crossref","unstructured":"Regan J, Lowe F. Enrichment medium for the isolation of Bordetella.J Clin Microbiol.\u20081977;6:303\u2013309","DOI":"10.1128\/jcm.6.3.303-309.1977"},{"key":"2021121006501233500_R19","unstructured":"Manclark CR, Meade BD, Burstyn DG. Serological response to Bordetella pertussis. In: Rose NR, Friedman H, Fahey JL, eds. Manual of Clinical Laboratory Immunology. 3rd ed. Washington, DC: American Society for Microbiology; 1986:388\u2013395"},{"key":"2021121006501233500_R20","doi-asserted-by":"crossref","unstructured":"Glare EM, Paton JC, Premier RR, et al. Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J Clin Microbiol.\u20081990;28:1982\u20131987","DOI":"10.1128\/jcm.28.9.1982-1987.1990"},{"key":"2021121006501233500_R21","doi-asserted-by":"crossref","unstructured":"Baughman AL, Bisgard KM. Need for equivalence testing of efficacy of alternative antibiotics for treatment of pertussis. Pediatr Infect Dis J.\u20082003;22:205\u2013207","DOI":"10.1097\/01.inf.0000050666.26000.34"},{"key":"2021121006501233500_R22","doi-asserted-by":"crossref","unstructured":"Barker L, Rolka H, Rolka D, et al. Equivalence testing for binomial random variables: which test to use?Am Stat.\u20082001;55:279\u2013287","DOI":"10.1198\/000313001753272213"},{"key":"2021121006501233500_R23","doi-asserted-by":"crossref","unstructured":"Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA.\u20082001;285:1987\u20131991","DOI":"10.1001\/jama.285.15.1987"},{"key":"2021121006501233500_R24","doi-asserted-by":"crossref","unstructured":"Bass J, Harden L. Treatment and prophylaxis failure of pertussis. Am J Dis Child.\u20081980;134:1178\u20131179 (letter)","DOI":"10.1001\/archpedi.1980.02130240058022"},{"key":"2021121006501233500_R25","doi-asserted-by":"crossref","unstructured":"Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr.\u20081996;129:761\u2013764","DOI":"10.1016\/S0022-3476(96)70163-4"},{"key":"2021121006501233500_R26","doi-asserted-by":"crossref","unstructured":"Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus erythromycin for the treatment of pertussis: a prospective, randomized, single blind trial. Pediatr Infect Dis J.\u20082001;20:1149\u20131154","DOI":"10.1097\/00006454-200112000-00011"},{"key":"2021121006501233500_R27","doi-asserted-by":"crossref","unstructured":"Bace A, Zrnic T, Begovac J, et al. Short-term treatment of pertussis with azithromycin in infants and young children. Eur J Clin Microbiol Infect Dis.\u20081999;18:296\u2013298","DOI":"10.1007\/s100960050281"},{"key":"2021121006501233500_R28","unstructured":"Steinberg JM, Srugo I. Reoccurrence of culture-positive pertussis in an infant initially treated with azithromycin and steroids. Arch Pediatr Adolesc Med.\u20082002;156:1057\u20131058"},{"key":"2021121006501233500_R29","doi-asserted-by":"crossref","unstructured":"Quigley EM, Hasler WL, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology.\u20082001;120:263\u2013286","DOI":"10.1053\/gast.2001.20516"},{"key":"2021121006501233500_R30","doi-asserted-by":"crossref","unstructured":"Klein JO. History of macrolide use in pediatrics. Pediatr Infect Dis J.\u20081997;16:427\u2013431","DOI":"10.1097\/00006454-199704000-00025"},{"key":"2021121006501233500_R31","doi-asserted-by":"crossref","unstructured":"Principi N, Esposito S, Blasi F, Allegra L. Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired lower respiratory tract infections. Clin Infect Dis.\u20082001;32:1281\u20131289","DOI":"10.1086\/319981"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/1\/e96\/1006283\/zpe00704000e96.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/114\/1\/e96\/1006283\/zpe00704000e96.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T15:45:44Z","timestamp":1639151144000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/114\/1\/e96\/64766\/Azithromycin-Is-as-Effective-as-and-Better"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,7,1]]},"published-print":{"date-parts":[[2004,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.114.1.e96","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,7,1]]}}}